scholarly journals Effects of Escitalopram on Markers of Bone Turnover: A Randomized Clinical Trial

2014 ◽  
Vol 99 (9) ◽  
pp. E1732-E1737 ◽  
Author(s):  
Susan J. Diem ◽  
Hadine Joffe ◽  
Joseph C. Larson ◽  
Joy N. Tsai ◽  
Katherine A. Guthrie ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bone Turnover ◽  
Randomized Clinical Trial ◽  
Markers Of Bone Turnover

scholarly journals Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical Trial

1998 ◽  
Vol 13 (9) ◽  
pp. 1431-1438 ◽  
Author(s):  
Susan L. Greenspan ◽  
Robert A. Parker ◽  
Lauren Ferguson ◽  
Harold N. Rosen ◽  
Lauri Maitland-Ramsey ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bone Turnover ◽  
Randomized Clinical Trial ◽  
Biochemical Markers ◽  
Elderly Women ◽  
Markers Of Bone Turnover ◽  
Term Response

scholarly journals Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

2011 ◽  
Vol 96 (2) ◽  
pp. 394-402 ◽  
Author(s):  
Paul D. Miller ◽  
Rachel B. Wagman ◽  
Munro Peacock ◽  
E. Michael Lewiecki ◽  
Michael A. Bolognese ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Clinical Trial ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Biochemical Markers ◽  
Phase 2 ◽  
Mineral Density ◽  
Markers Of Bone Turnover ◽  
Phase 2 Clinical Trial

scholarly journals Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

2012 ◽  
Vol 24 (1) ◽  
pp. 227-235 ◽  
Author(s):  
M. R. McClung ◽  
E. M. Lewiecki ◽  
M. L. Geller ◽  
M. A. Bolognese ◽  
M. Peacock ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Clinical Trial ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Biochemical Markers ◽  
Phase 2 ◽  
Mineral Density ◽  
Markers Of Bone Turnover ◽  
Phase 2 Clinical Trial

scholarly journals A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma

2009 ◽  
Vol 27 (1) ◽  
pp. 17-22 ◽  
Author(s):  
TE Sondergaard ◽  
PT Pedersen ◽  
TL Andersen ◽  
K Søe ◽  
T Lund ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Multiple Myeloma ◽  
Bone Turnover ◽  
Beneficial Effect ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
High Dose ◽  
Markers Of Bone Turnover

Effect of the ERα agonist GTx-758 on bone turnover markers in men with advanced prostate cancer.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 222-222
Author(s):  
Evan Y. Yu ◽  
Thomas E. Keane ◽  
Ronald Tutrone ◽  
Laurence Belkoff ◽  
Joel Bass ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Alkaline Phosphatase ◽  
Bone Turnover ◽  
Phase Ii ◽  
Advanced Prostate Cancer ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
Markers Of Bone Turnover ◽  
Venous Thromboembolic Events

222 Background: Men with advanced prostate cancer are being treated with androgen deprivation therapy (ADT) for longer periods of time. The use of ADT can be limited by estrogen deficiency side effects, including a loss of bone and a higher incidence of fractures. GTx-758 is an ERα agonist that lowers serum free testosterone greater than an LHRH agonist. Herein we compare the effects of GTx-758 and leuprolide on markers of bone turnover, C-terminal telopeptides and bone specific alkaline phosphatase, in men with advanced prostate cancer treated with ADT. Methods: In a Phase II study (G200705), men with advanced prostate cancer (n=159) received 1000 mg or 2000 mg of GTx-758 daily or leuprolide. Serum samples were collected and analyzed by a reference laboratory. C-terminal telopeptides (pg/ml) and bone specific alkaline phosphatase (U/L) were measured as indicators of bone turnover. All p values describe the comparison of the GTx-758 treatment groups to the leuprolide treated men at day 120. Results: Men receiving the 1000 mg and 2000 mg doses of GTx-758 had lower C-terminal telopeptide levels with a mean percentage change of -56.9 ± 12.5 and -54.8 ± 23.1, respectively, as compared with an increase of 46.0 ± 48.9 percentage in the men receiving the leuprolide (p<0.001). Similarly, bone specific alkaline phosphatase levels were lower in men treated with GTx-758, with mean percentage changes of-28.5 ± 11.7 and -19.8 ± 14.7, respectively, compared with an increase of 8.1 ± 24.3 percent in the leuprolide treated group (p<0.001). As a result of an increased risk of venous thromboembolic events (VTEs) at these higher doses of GTx-758, the trial was stopped prior to its completion and not all of the men on the study reached the 120 day treatment dates (71 evaluable). Conclusions: Patients receiving GTx-758 experienced a significant decrease in markers of bone turnover indicating potential improvement and not a loss of bone on ADT. Since changes in bone mineral density are a major side effect that can negatively affect the quality of life in men on ADT, the improvements in bone turnover observed in men treated with GTx-758 could be significant. A Phase II clinical trial utilizing lower doses of GTx-758 (G200712) is currently being performed. Clinical trial information: NCT01326312.

Randomized clinical trial of LigasureTM versus open haemorrhoidectomy

2002 ◽  
Vol 89 (2) ◽  
pp. 154-157 ◽  
Author(s):  
F. F Palazzo ◽  
D. L Francis ◽  
M. A Clifton
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial
Sign in / Sign up

Export Citation Format

Share Document